Montaño-Loza A, Meza-Junco J

Idioma: Español
Referencias bibliográficas: 83
Paginas: 596-607
Archivo PDF: 187.15 Kb.

RESUMEN

Actualmente está bien establecido que la hipertensión portal no es un fenómeno puramente mecánico. En esta entidad se presentan alteraciones hemodinámicas primarias en los sistemas circulatorios hepático y sistémico; estas alteraciones en combinación con factores mecánicos, contribuyen al desarrollo de la hipertensión portal. En la circulación hepática, las alteraciones hemodinámicas se caracterizan por vasoconstricción y una respuesta anómala a la vasodilatación, mientras que en la circulación sistémica, especialmente en el lecho esplácnico, los vasos están congestivos y con un flujo aumentado. Por lo tanto un incremento en las resistencias intrahepáticas asociado a un aumento del flujo venoso portal, mediado a través de la dilatación esplácnica, contribuyen al desarrollo de la hipertensión portal. La consecuencia del flujo y la presión transmural elevada a través de los vasos colaterales a partir de una vasculatura portal hipertensa hacia la circulación venosa sistémica con menor presión, conlleva a muchas de las complicaciones observadas en la hipertensión portal, como la hemorragia por várices esofágicas. La importancia del origen vascular primario de la hipertensión portal se basa en la utilidad de terapias actuales orientadas a revertir estas alteraciones hemodinámicas, como los nitratos que reducen la presión portal, a través de vasodilatación intrahepática directa y los b bloqueadores y octreótida, que reducen la vasodilatación esplácnica y el flujo venoso portal. Además, existen nuevas evidencias en relación con los mecanismos moleculares de vías de señalización contráctil de las células estelares hepáticas y complejas vías de regulación de sustancias vasoactivas en las células endoteliales hepáticas que han ayudado a entender mejor estos procesos esenciales para el desarrollo de terapias experimentales para la hipertensión portal. Este artículo revisa los conceptos actuales relacionados con los mecanismos celulares causales de las alteraciones hemodinámicas que caracterizan y condicionan el desarrollo de la hipertensión portal.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Huet PM, Pomier-Layrargues G, Villeneuve JP, et al. Intrahepatic circulation in liver disease. Semin Liver Dis 1986; 6: 277-86.

2. Boyer TD. Portal hypertensive hemorrhage: pathogenesis and risk factors. Semin Gastrointest Dis 1995; 6: 125-33.

3. Kapoor D, Sarin SK. Pathophysiology of portal hypertension. J Gatroenterol Hepatol 2002; 17: S482-S487.

4. Benoit JN, Granger DN. Splanchnic hemodynamics in chronic portal hypertension. Semin Liver Dis 1986; 6: 287-98.

5. Lebrec D, Moreau R. Pathogenesis of portal hypertension. Eur J Gastroenterol Hepatol 2001; 13: 309-11.

6. Ekataksin W, Kaneda K. Liver microvascular architecture: an insight into the pathophysiology of portal hypertension. Semin Liver Dis 1999: 19: 359-82.

7. Groszmann RJ, Atterbury CE. The pathophysiology of portal hypertension. Semin Liver Dis 1982; 2: 177-86.

8. Sandblom P. The history of portal hypertension. J R Soc Med 1993; 86: 544-6.

9. Polio J, Groszmann RJ. Hemodynamic factors involved in the development and rupture of esophageal varices: a pathophysiologic approach to treatment. Semin Liver Dis 1986; 6: 318-31.

10. Lebrec D, Bataille C, Bercoff E, et al. Hemodynamic changes in patients with portal venous obstruction. Hepatology 1983; 3: 550-3.

11. Garcia-Tsao G. Current management of the complications of cirrhosis and portal hypertension: varices and variceal hemorrhage, ascites and spontaneous bacterial peritonitis. Gastroenterology 2001; 120: 726-48.

12. Mendez-Sanchez N, Aguilar-Ramirez JR, Reyes A, et al. Etiology of liver cirrhosis in Mexico. Ann Hepatol 2004; 3: 30-3.

13. Raia S, Mies S, Macedo AL. Portal hypertension in schistosomiasis. Clin Gastroenterol 1985; 14: 57-82.

14. Lebrec D, Benhamou JP. Noncirrhotic intrahepatic portal hypertension. Semin Liver Dis 1986; 6: 332-40.

15. Da Silva LC, Carrilho FJ. Hepatosplenic schistosomiasis: Pathophysiology and treatment. Gastroenterol Clin North Am 1992; 21: 163-77.

16. Ludwig J, Hashimoto E, Obata H, et al. Idiopathic portal hypertension. Hepatology 1993; 17: 1157-62.

17. Hillaire A, Bonte E, Denninger MH, et al. Idiopathic non-cirrhotic intrahepatic portal hypertension in the West: a re-evaluation in 28 patients. Gut 2002; 51: 275-80.

18. Benhamou JP, Valla DC. Intrahepatic portal hypertension. In: Bircher J, Benhamou JP, McIntyre N, et al, eds. Oxford textbook of clinical hepatology, 2nd edn. Oxford: Oxford University Press; 1999, p. 661-70.

19. Wanless IR, Wong F, Blendis LM, et al. Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. Hepatology 1995; 21: 1238-47.

20. Rockey DC. Cellular pathophysiology of portal hypertension and prospects for management with gene therapy. Clin Liver Dis 2001; 5: 851-65.

21. Pinzani M, Gentilini P. Biology of hepatic stellate cells and their possible relevance in the pathogenesis of portal hypertension in cirrhosis. Semin Liver Dis 1999; 19: 397-410.

22. Moller S, Bendtsen F, Heriksen JH. Vasoactive substances in the circulatory dysfunction of cirrhosis. Scand J Clin Lab Invest 2001; 61: 421-9.

23. Alam I, Bass NM, Bacchett P, et al. Hepatic tissue levels of endothelin-1 correlate with severity of chronic liver disease and ascites. Am J Gastroenterol 2000; 95: 199-203.

24. Reynaert H, Thompson MG, Thomas T, et al. Hepatic stellate cells: role in microcirculation and pathophysiology of portal hypertension. Gut 2002; 50: 571-81.

25. Lautt WW. Hepatic vasculature: a conceptual review. Gastroenterology 1977; 73: 1163-69.

26. Chan CC, Wang SS, Lee FY, et al. Effects of endothelin-1 on portal-systemic collaterals of common bile duct-ligated cirrhotic rats. Eur J Clin Invest 2004; 34: 290-6.

27. Fernandez M, Vizzutti F, Garcia-Pagan JC, et al. Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice. Gastroenterology 2004; 126: 886-94.

28. Matsubara S, Ouchi K, Matsuno S. Portal venous pressure following splenectomy in patients with portal hypertension of differing etiology. Eur Surg Res 1992; 24: 372-7.

29. Vauthey JN, Tomczak RJ, Helmberger T, et al. The arterioportal fistula syndrome: clinicopathologic features, diagnosis, and therapy. Gastroenterology 1997; 113: 1390-401.

30. Kamel IR, Lawler LP, Corl FM, et al. Patterns of collateral pathways in extrahepatic portal hypertension as demonstrated by multidetector row computed tomography and advanced image processing. J Comput Assist Tomogr 2004; 28: 469-77.

31. Roberts LR, Kamath PS. Pathophysiology of variceal bleeding. Gastrointest Endosc Clin North Am 1999; 9: 167-74.

32. Rector WG Jr., Hoefs JC, Hossack KF, et al. Hepatofugal portal flow in cirrhosis: observations on hepatic hemodynamics and the nature of the arterioportal communications. Hepatology 1988; 8: 16-20.

33. Gaiani S, Bolondi L, Li Bassi S, et al. Prevalence of spontaneous hepatofugal portal flow in liver cirrhosis: clinical and endoscopic correlation in 228 patients. Gastroenterology 1991; 100: 160-7.

34. Sugita S, Ohnishi K, Saito M, et al. Splanchnic hemodynamics in portal hypertensive dogs with portal fibrosis. Am J Physiol 1987; 252: G748-G754.

35. Nishida O, Moriyasu F, Nakamura T, et al. Interrelationship between splenic and superior mesenteric venous circulation manifested by transient splenic arterial occlusion using a balloon catheter. Hepatology 1987; 7: 442-6.

36. Strassburg CP. Gastrointestinal disorders of the critically ill. Shock liver. Best Pract Res Clin Gastroenterol 2003; 17: 369-81.

37. Ready J, Rector WG Jr. Systemic hemodynamic changes in portal hypertension. Semin Gastrointest Dis 1995; 6: 134-9.

38. Groszmann RJ. Hyperdynamic circulation of liver disease 40 years later: pathophysiology and clinical consequences. Hepatology 1994; 20: 1359-63.

39. Abelmann WH. Hyperdynamic circulation in cirrhosis: a historical perspective. Hepatology 1994; 20: 1356-8.

40. Meng HC, Lin HC, Tsai YT, et al. Relationships between the severity of cirrhosis and haemodynamic values in patients with cirrhosis. J Gastroenterol Hepatol 1994; 9: 148-53.

41. Lange PA, Stoller JK. The hepatopulmonary syndrome. Ann Intern Med 1995; 122: 521-9.

42. Hoeper MM, Krowka MJ, Strassburg CP. Portopulmonary hypertension and hepatopulmonary syndrome. Lancet 2004; 363: 1461-68.

43. Schrier RW, Arroyo V, Bernardi M, et al. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988; 8: 1151-7.

44. Rector WG Jr., Robertson AD, Lewis FW, et al. Arterial underfilling does not cause sodium retention in cirrhosis. Am J Med 1993; 95: 286-95.

45. García-Pagán JC, Bosch J, Rodés J. The role of vasoactive mediators in portal hypertension. Semin Gastrointest Dis 1995; 6: 140-7.

46. García-Pagán JC, Escorsell A, Moitinho E, et al. Influence of pharmacological agents on portal hemodynamics: basis for its use in the treatment of portal hypertension. Semin Liver Dis 1999; 19: 427-38.

47. Colle IO, De Vriese AS, Van Vlierberghe HR, et al. Vascular hyporesponsiveness in the mesenteric artery of anaesthetized rats with cirrhosis and portal hypertension: an in-vivo study. Eur J Gastroenterol Hepatol 2004; 16: 139-45.

48. Wiest R, Groszmann RJ. Nitric oxide and portal hypertension: its role in the regulation of intrahepatic and splanchnic vascular resistance. Semin Liver Dis 1999; 19: 411-26.

49. Silva G, Navasa M, Bosch J, et al. Hemodynamic effects of glucagon in portal hypertension. Hepatology 1990; 11: 668-73.

50. Pizcueta MP, Casamitjana R, Bosch J, et al. Decreased systemic vascular sensitivity to norepinephrine in portal hypertensive rats: role of hyperglucagonism. Am J Physiol 1990; 258: G191-G195.

51. Benoit JN, Zimmermann B, Preman AJ, et al. Role of glucagon in splanchnic hyperemia of chronic portal hypertension. Am J Physiol 1986; 251: G674-G647.

52. Tsui CP, Sung JJ, Leung FW. Role of acute elevation of portal venous pressure by exogenous glucagon on gastric mucosal injury in rats with portal hypertension. Life Sci 2003; 73: 1115-29.

53. Sikuler E, Groszmann RJ. Hemodynamic studies in long-and short-term portal hypertensive rats: the relation to systemic glucagon levels. Hepatology 1986; 6: 414-8.

54. Albillos A, Colombato LA, Lee FY. Octreotide ameliorates vasodilation and Na+ retention in portal hypertensive rats. Gastroenterology 1993; 104: 575-9.

55. Cao K, Tang G, Hu D, Wang R. Molecular basis of ATP-sensitive K+ channels in rat vascular smooth muscles. Biochem Biophys Res Commun 2002; 296: 463-9.

56. Moreau R, Chagneau C, Heller J, et al. Hemodynamic, metabolic and hormonal responses to oral glibenclamide in patients with cirrhosis receiving glucose. Scand J Gastroenterol 2001; 36: 303-8.

57. Bomzon A, Blendis LM. The nitric oxide hypothesis and the hyperdynamic circulation in cirrhosis. Hepatology 1994; 20: 1343-50.

58. Sogni P, Moreau R, Gadano A, et al. The role of nitric oxide in the hyperdynamic circulatory syndrome associated with portal hypertension. J Hepatol 1995; 23: 218-24.

59. Lopez-Talavera JC, Merrill WW, Groszmann RJ. Tumor necrosis factor alpha: a major contributor to the hyperdynamic circulation in prehepatic portal-hypertensive rats. Gastroenterology 1995; 108: 761-7.

60. Theodorakis NG, Wang YN, Skill NJ, et al. The role of nitric oxide synthase isoforms in extrahepatic portal hypertension: studies in gene-knockout mice. Gastroenterology 2003; 124: 1500-8.

61. Wang JJ, Gao GW, Gao RZ, et al. Effects of tumor necrosis factor, endothelin and nitric oxide on hyperdynamic circulation of rats with acute and chronic portal hypertension. World J Gastroenterol 2004; 10: 689-93.

62. Guarner C, Soriano G, Tomas A, et al. Increased serum nitrite and nitrate levels in patients with cirrhosis: relationship to endotoxemia. Hepatology 1993; 18: 1139-43.

63. Tsai MH, Iwakiri Y, Cadelina G, et al. Mesenteric vasoconstriction triggers nitric oxide overproduction in the superior mesenteric artery of portal hypertensive rats. Gastroenterology 2003; 125: 1452-61.

64. García-Pagan JC, Fernández M, Bernadich C, et al. Effects of continued nitric oxide inhibition on the portal hypertensive syndrome after portal vein stenosis in the rat. Am J Physiol 1994; 30: 984-90.

65. Grange JD, Amiot X. Related articles, links nitric oxide and renal function in cirrhotic patients with ascites: from physiopathology to practice. Eur J Gastroenterol Hepatol 2004; 16: 567-70.

66. Guarner C, Soriano G. Prostaglandin and portal hypertension. Prostaglandins Leukot Essent Fatty Acids 1993; 48: 203-6.

67. Guarner C, Soriano G, Such J, et al. Systemic prostacyclin in cirrhotic patients. Relationship with portal hypertension and changes after intestinal decontamination. Gastroenterology 1992; 102: 303-9.

68. Ackerman Z, Karmeli F, Rachmilewitz D. Longitudinal prostaglandin E2 generation in various organs during evolution of experimental portal hypertension. Prostaglandins Leukot Essent Fatty Acids 2002; 67: 197-201.

69. Birney Y, Redmond EM, Sitzmann JV, et al. Eicosanoids in cirrhosis and portal hypertension. Prostaglandins Other Lipid Mediat 2003; 72: 3-18.

70. Yokoyama Y, Toth B, Kitchens WC, et al. Role of thromboxane in producing portal hypertension following trauma-hemorrhage. Am J Physiol Gastrointest Liver Physiol 2003; 285: G1293-G1299.

71. Gonzalez-Garcia M, Albillos-Martinez A. Pharmacological modulation of portal hypertension syndrome: current status and future prospects. Gastroenterol Hepatol 2004; 27(Suppl 1): 1-7.

72. Kawada N, Tran-Thi TA, Klein H, et al. The contraction of hepatic stellate cells stimulated with vasoactive substances. Possible involvement of endothelin-1 and nitric oxide in the regulation of sinusoidal tonus. Eur J Biochem 1993; 213: 815-23.

73. Zhang JX, Pegoli W, Clemens MG. Endothelin-1 induces direct constriction of hepatic sinusoids. Am J Physiol 1994; 266: G624-G632.

74. Levin ER. Endothelins. N Engl J Med 1995; 333: 356-63.

75. Reichen J, Gerbes AL, Steiner MJ, et al. The effect of endothelin and its antagonist Bosentan on hemodynamics and microvascular exchange in cirrhotic rat liver. J Hepatol 1998; 28: 1020-30.

76. Thirunavukkarasu C, Yang Y, Subbotin VM, et al. Endothelin receptor antagonist TAK-044 arrests and reverses the development of carbon tetrachloride induced cirrhosis in rats. Gut 2004; 53: 1010-19.

77. Ginès P, Cardenas A, Arroyo V, et al. Management of cirrhosis and ascites. N Engl J Med 2004; 350: 1646-54.

78. Garcia-Tsao G, Weist R. Gut microflora in the pathogenesis of the complications of cirrhosis. Best Pract Res Clin Gastroenterol 2004; 18: 353-72.

79. Wiest R, Das S, Cadelina G, et al. Bacterial translocation to lymph nodes of cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. J Clin Invest 1999; 104: 1223-33.

80. Wiest R, Tsai MH, Garcia-Tsao G, et al. Bacterial translocation up-regulates GTP-cyclohydrolase I in mesenteric vasculature of cirrhotic rats. Hepatology 2003; 38: 1508-15.

81. Albillos A, de la Hera A, Gonzalez M, et al. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology 2003; 37: 208-17.

82. Chin-Dusting JP, Rasaratnam B, Jennings JL, et al. Effect of fluoroquinolone on the enhanced nitric oxide-induced peripheral vasodilation seen in cirrhosis. Ann Intern Med 1997; 127: 985-8.

83. Rabiller A, Nunes H, Lebrec D, et al. Prevention of gram-negative translocation reduces the severity of hepatopulmonary syndrome. Am J Resp Crit Care Med 2002; 166: 514-17.